Gene: ATP13A3
Official Full Name: ATPase 13A3provided by HGNC
Gene Summary: ATP13A3 is a member of the P-type ATPase family of proteins that transport a variety of cations across membranes. Other P-type ATPases include ATP7B (MIM 606882) and ATP7A (MIM 300011).[supplied by OMIM, Aug 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO19553 | ATP13A3 Knockout cell line (HeLa) | Human | ATP13A3 | 1:3~1:6 | Negative | Online Inquiry |
KO19554 | ATP13A3 Knockout cell line (HCT 116) | Human | ATP13A3 | 1:2~1:4 | Negative | Online Inquiry |
KO19555 | ATP13A3 Knockout cell line (HEK293) | Human | ATP13A3 | 1:3~1:6 | Negative | Online Inquiry |
KO19556 | ATP13A3 Knockout cell line (A549) | Human | ATP13A3 | 1:3~1:4 | Negative | Online Inquiry |
ATP13A3 Gene Knockout Cell Lines represent a sophisticated tool engineered for the study of the ATP13A3 gene, which is implicated in lysosomal function and various neurological disorders. These cell lines are created through the precise editing of the ATP13A3 gene, enabling researchers to investigate the biological consequences of gene loss and the pathways it influences. By eliminating the expression of ATP13A3, these knockout cell lines provide a robust platform for uncovering the gene's role in cellular processes such as autophagy, metal ion transport, and neurological signaling.
The key mechanism behind these cell lines involves the utilization of CRISPR-Cas9 technology, allowing for targeted genomic alterations with high precision. This approach not only enhances the reliability of data obtained in various experimental setups but also facilitates the investigation into potential therapeutic targets for diseases linked to ATP13A3 dysfunction. In research settings, ATP13A3 knockout models can serve as invaluable platforms for drug screening, functional assays, and studies focusing on disease pathology.
From a scientific perspective, the implications of ATP13A3 research extend to understanding conditions such as Kufor-Rakeb syndrome and other neurodegenerative diseases. By utilizing these specialized cell lines, clinicians and researchers can gain profound insights into disease mechanisms, potentially leading to the development of novel therapeutic strategies.
What distinguishes ATP13A3 Gene Knockout Cell Lines from alternatives on the market is their rigorously validated lifecycle and the comprehensive support provided by our organization. This ensures that users can trust the robustness and reproducibility of their experiments. Our commitment to quality and innovation means that we not only supply superior biological products but also empower researchers and clinicians in their quest for breakthrough discoveries. As a leader in genetic engineering solutions, our expertise ensures that you receive the most advanced tools for your research needs.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.